Gilead Sciences Gross Unrealized Gains decreased by 90.9% to $1.00M in Q1 2026 compared to the prior quarter. Over 4 years (FY 2020 to FY 2025), Gross Unrealized Gains shows an upward trend with a 38.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates favorable market conditions for the fixed-income portfolio, potentially boosting book value.
The total amount of unrealized gains on debt securities classified as available-for-sale that have not yet been recogniz...
Standard metric for insurance companies holding large bond portfolios.
other_available_for_sale_debt_securities_accumulated_gro_8d5dbc| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $1.00M | $0.00 | $0.00 | $0.00 | $0.00 | $1.00M | $2.00M | $0.00 | $0.00 | $5.00M | $6.00M | $10.00M | $11.00M | $1.00M |
| QoQ Change | — | +0.0% | -100.0% | — | — | — | — | +100.0% | -100.0% | — | — | +20.0% | +66.7% | +10.0% | -90.9% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | — | — | — | — | +400.0% | — | — | — | — |